Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism

Cancer Science

Volumn 101, Issue 3, 2010, Pages 722-727

  Hazama, Shoichi ^a   Nagashima, Atsushi ^a   Kondo, Hiroshi ^a   Yoshida, Shin ^a   Shimizu, Ryoichi ^a   Araki, Atsuhiro ^a   Yoshino, Shigefumi ^a   Okayama, Naoko ^a   Hinoda, Yuji ^a   Oka, Masaaki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; DOXIFLURIDINE; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; EVENING DOSAGE; FATIGUE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MORNING DOSAGE; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLOXURIDINE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC;

EID: 77949755095     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01428.x     Document Type: Article

References (30)

1. Douillard JY, Cunningham D, Roth AD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-7.
2. Saltz LB, Cox JV, Blanke C. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-14.
3. Tournigand C, Andre T, Achille E. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-37.
4. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991, 51:4187-91.
5. Iyer L, King CD, Whitington PF. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998, 101:847-54.
6. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998, 95:8170-4.
7. Ando Y, Saka H, Ando M. Polymorphisms of UDP-glucu-ronosyltransferasegene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000, 60:6921-6.
8. Massacesi C, Terrazzino S, Marcucci F. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006, 106:1007-16.
9. Innocenti F, Undevia SD, Iyer L. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004, 22:1382-8.
10. Miwa M, Ura M, Nishida M. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998, 34:1274-81.
11. Armstrong RD, Cadman E. 5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. Cancer Res 1983, 43:2525-8.
12. Alberto P, Mermillod B, Germano G. A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. Eur J Cancer Clin Oncol 1988, 24:559-63.
13. Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-16.
14. Wang L, Hirayasu K, Ishizawa M, Kobayashi Y. Purification of genomic DNA from human whole blood by isopropanol-fractionation with concentrated Nal and SDS. Nucleic Acids Res 1994, 22:1774-5.
15. Okayama N, Hamanaka Y, Suehiro Y, Hasui Y, Nakamura J, Hinoda Y. Association of interleukin-10 promoter single nucleotide polymorphisms -819 T/C and -592 A/C with aging. J Gerontol A Biol Sci Med Sci 2005, 60:1525-9.
16. Sparreboom A, de Bruijn P, de Jonge MJ. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr B Biomed Sci Appl 1998, 712:225-35.
17. Araki K, Fujita K, Ando Y. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 2006, 97:1255-9.
18. Ura T, Satoh T, Tsujinaka T. A genotype-directed dose-finding study of irinotecan based on UGT1A1 *28 and *6 polymorphisms in Japanese patients with gastrointestinal cancer (UGT0601). Ann Oncol 2008, 19(Suppl):abstr 406P.
19. Esaki T, Satoh T, Ura T. A prospective PGx and PK/PD dose-finding study of irinotecan based on UGT1A1*6 and *28 genotyping (UGT0601). J Clin Oncol 2009, 27(Suppl):abstr e14560.
20. Kim T, Sym S, Lee S. A UGT1A1 genotype-directed phase I study of irinotecan (CPT-11) combined with fixed dose of capecitabine in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2009, 27(Suppl):abstr 2554.
21. Toffoli G, Cecchin E, Corona G. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006, 24:3061-8.
22. Mathijssen RH, Marsh S, Karlsson MO. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003, 9:3246-53.
23. Stewart CF, Panetta JC, O'Shaughnessy MA. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007, 25:2594-600.
24. Han JY, Lim HS, Shin ES. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006, 24:2237-44.
25. Minami H, Sai K, Saeki M. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007, 17:497-504.
26. Saito Y, Sai K, Maekawa K. Close association of UGT1A9 IVS1 + 399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab Dispos 2009, 37:272-6.
27. Yamamoto N, Takahashi T, Kunikane H. Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Ther 2009, 85:149-54.
28. Lankisch TO, Schulz C, Zwingers T. Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 2008, 17:695-701.
29. Fujita K, Ando Y, Nagashima F. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 2007, 60:515-22.
30. Sai K, Saito Y, Sakamoto H. Importance of UDP-glucurono-syltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett 2008, 261:165-71.